Highlights of the San Antonio Breast Cancer Symposium 2021

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2021.

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies

Professor Lisa A. Carey speaks about the MONALEESA-2, -3, and -7 trials of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer.

Final results of KEYNOTE-355

Professor Javier Cortes speaks about the final results of KEYNOTE-355 trial, a Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer

Professor Michael Gnant speaks about the final results from 5,760 patients in the randomized phase III PALLAS trial.

The DESTINY-Breast03 trial

Professor Sara Hurvitz speaks about trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2+ metastatic breast cancer.

Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Prof. Peter Galle speaks about the emerging therapies on advanced RCC, HCC and DTC.

The MONALEESA-2 trial

Prof. Gabriel N. Hortobagyi speaks about the overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative advanced breast cancer treated with endocrine therapy ± ribociclib.

Should Cure Be A Reasonable Goal in aRCC?

Prof. David F. McDermott speaks about the long-term survival of patients with kidney cancer.

Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?

Prof. Alessandra Curioni speaks about the update of CheckMate 743 trial.

The Keynote 716 trial

Prof. Jason J. Luke speaks about the efficacy and safety results from the  Keynote 716 double-blinded phase III trial. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma.

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Prof. Judy King speaks about the treatment of HER2+ Metastatic Breast Cancer.

Metastases-free survival results from STAMPEDE trial

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Highlights of the ESMO 2021 Congress

Prof. Solange Peters speaks about the most important presentations on ESMO 2021.

Expanded efficacy and safety data from CheckMate 649

Prof.  Markus Moehler speaks about CheckMate 649 trial (first-line nivolumab plus chemotherapy versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma).

Current state of frontline immunotherapy options in the treatment of NSCLC

Prof.  Federico Cappuzzo, Director of Medical Oncology in National Cancer Institute from Italy summarize the current state of frontline immunotherapy options in the treatment of NSCLC both in early stage and in metastatic advanced disease.

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)